

Technology Advisory Interests Register

Topic: Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Satish Venkateshan	TAC Committee Member	Direct- financial	Regeneron is developing therapeutics for a broad range of diseases including in ophthalmology. Satish works for Regeneron, pharmaceuticals/biotech company. He also owns shares in the company and have stock options.	22/01/2025 17/06/2025	It was agreed Satish's declaration would not prevent them from participating in this appraisal
Professor Patrick Yu Wai Man	Clinical Expert	Direct- financial Indirect- financial	Professor Patrick Yu Wai Man has acted as a consultant for Chiesi (manufacturer) and GenSight Biologics. (comparator) Professor Patrick Yu Wai Man has been involved in clinical studies looking at idebenone (RHODOS and LEROS). Professor Yu Wai Man is also involved in the ongoing gene therapy programme (GS010, Lumevoq) for patients with the m.11778G>A mitochondrial DNA mutation (RESCUE, REVERSE and REFLECT).	18/09/2023 08/07/2025	It was agreed that Professor Patrick Yu Wai Man's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Marcela Votruba	Clinical Expert	Direct- financial	Professor Marcela Votruba has received payments for speaking engagements and sitting on advisory boards. Chiesi Scandinavian Advisory Board (virtual) participated as Adviser J8th June 2023.They also attended Chiesi Advisory Board Nov 2024.	14/09/2023 08/07/2025	It was agreed that Professor Marcela Votruba's declaration would not prevent her from providing expert advice to the committee.
Lily Mumford	Patient Expert	Direct – non-financial	Compassionate Use supply of Idebenone from originator company	15/09/2023	It was agreed that Lily's declaration would not prevent them from providing expert advice to the committee.